Improved Outcomes in Juvenile Idiopathic Arthritis Following Antihistamine Treatment in Patients with Concurrent Allergic Rhinitis
|Ruru Guo, Lanfang Cao*, Xianming Kong, Haiyan Xue, Xiaoli Li and Lijuan Shen|
|Department of Pediatrics (R.R.G., L.F.C., X.M.K., H.Y.X., X.L.L.,L.J.S.), Renji Hospital, School of Medicine, Shanghai Jiaotong University, 1630 Dongfang Rd, Shanghai 200127, P. R. China|
|Corresponding Author :||Lanfang Cao
Department of Pediatrics (R.R.G., L.F.C., X.M.K., H.Y.X., X.L.L.,L.J.S.)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
1630 Dongfang Rd, Shanghai 200127, P. R. China
Tel: +86 18817821418
Fax: +86 2153882035
E-mail: [email protected]
|Received: December 20, 2015 Accepted: December 28, 2015 Published: December 31, 2015|
|Citation: Guo R, Cao L, Kong X, Xue H, Li X, et al. (2015) Improved Outcomes in Juvenile Idiopathic Arthritis Following Antihistamine Treatment in Patients with Concurrent Allergic Rhinitis. J Arthritis S1:009. doi:10.4172/2167-7921.S1-009|
|Copyright: © 2015 Guo R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at Pubmed, Scholar Google|
Objective: We aim to assess the influence of antihistamines as an adjunctive therapy in children with JIA who also have co-existing mild to moderate AR.
Methods: Fifty-two JIA patients with AR were enrolled and consecutively randomized. The control group comprised 26 patients who were treated with methotrexate (MTX) 10-15 mg/m2/week orally for 12 months and enteric-coated diclofenac sodium 0.5-2 mg/kg/day orally for 12 weeks. The test group comprised 26 patients who received adjunctive therapy with oral and intranasal antihistamines for 12 months, in addition to MTX and diclofenac. The responses were evaluated using American College of Rheumatology (ACR) pediatric (Pedi) 30/50/70 criteria, AR score, 27-joint Juvenile Arthritis Disease Activity Score (JADAS-27), and laboratory variables.
Results: At 3 and 6 months follow-up, significantly more patients in the antihistamine treatment group achieved ACR Pedi50 and ACR Pedi70 responses(at 3 months, 73.1% to 19.2%, 38.5% to 7.7%; at 6 months, 96.2% to 53.8%, 76.9% to 19.2%, respectively, all p<0.01). In the antihistamine group the AR score correlated with JADAS-27 at baseline, 3 months and 6 months (r=0.946, r=0.909 and r=0.964, respectively). During 12 months of follow-up, there were significantly fewer JIA flares in the antihistamine group (0.8 ± 0.7 vs. 2.2 ± 1.4, p<0.01).
Conclusions: JIA patients with concurrent AR who receive effective antihistamine treatment for their AR may have better outcomes in terms of JIA control.